A
Akhil Chopra
Researcher at Johns Hopkins University
Publications - 29
Citations - 3901
Akhil Chopra is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Nivolumab & Sorafenib. The author has an hindex of 12, co-authored 29 publications receiving 2765 citations.
Papers
More filters
Journal ArticleDOI
Comparative effective analysis between enzalutamide and abiraterone in the treatment of metastatic castration-resistant prostate cancer.
TL;DR: E appears to be more effective than A in terms of time to PSA progression, rPFS and PSA response, and in this indirect comparative effectiveness analysis.
Journal ArticleDOI
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
Ignacio Melero,Bruno Sangro,Thomas Yau,C.-H. Hsu,Masatoshi Kudo,Todd S. Crocenzi,Tae Yong Kim,Su Pin Choo,Joerg Trojan,Tim Meyer,Theodore H. Welling,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,C.l.a. De Cruz,Lixin Lang,Jaclyn Neely,Anthony B. El-Khoueiry +17 more
Journal ArticleDOI
195OEfficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study
S.P. Choo,Thomas Yau,C.-H. Hsu,Y-K Kang,M-M Hou,Winnie Yeo,Kazushi Numata,Akhil Chopra,Adyb Baakili,C dela Cruz,Huanyu Zhao,Masatoshi Kudo +11 more
Journal ArticleDOI
Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study
Ignacio Melero,Anthony B. El-Khoueiry,Thomas Yau,Chiun Hsu,Masatoshi Kudo,Todd S. Crocenzi,Tae-You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Adyb Baakili,Christine Dela Cruz,Huanyu Zhao,Bruno Sangro,Tim Meyer +17 more
Journal ArticleDOI
Cost-effectiveness evaluation of abiraterone in the treatment of patients with castration-resistant prostate cancer who previously received docetaxel.
TL;DR: A decision-analytical model was created using clinical data from the pivotal phase III trial: COU-AA-301 to assess the cost-effectiveness of abiraterone in the treatment of advanced CRPC patients, from a payer perspective.